0001004878-17-000204.txt : 20170831
0001004878-17-000204.hdr.sgml : 20170831
20170831173043
ACCESSION NUMBER: 0001004878-17-000204
CONFORMED SUBMISSION TYPE: 424B3
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20170831
DATE AS OF CHANGE: 20170831
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 424B3
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-205444
FILM NUMBER: 171064044
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
424B3
1
prospsuppddee8-17.txt
PRO SUPP SERIES DD & EE WARRANTS
PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement Registration No. 333-205444
dated December 8, 2016)
CEL-SCI CORPORATION
Series DD and Series EE Warrants
On August 29, 2017 the Company extended the expiration date of its Series DD and
Series EE warrants until the close of business on December 1, 2017. The Series
DD and Series EE warrants were issued as part of a financing on December 8,
2016. As a result of the reverse stock split approved by the Company's
shareholders and adopted by the Company's directors:
o the holders of the Series DD warrants are entitled to purchase
1,360,960 shares of the Company's common stock at an exercise price of
$4.50 per share; and
o the holders of the Series EE warrants are entitled to purchase
1,360,960 shares of the Company's common stock at an exercise price of
$4.50 per share.
Prospectus Supplement dated August 29, 2017